+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study



Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study



Bju International 104(6): 806-812



To investigate changes in bone mineral density (BMD) and osteoporosis, over 3 years of intermittent androgen-suppression therapy (IAST). This was a Phase II individual cohort study of 72 patients with prostate cancer without metastatic bone disease, enrolled between 1999 and 2002. Patients had 9 months flutamide (250 mg, three times daily) and leuprolide (22.5 mg, 3-monthly depot) after which, patients ceased therapy providing that their PSA levels were <4 ng/mL. AST re-commenced when the PSA level exceeded the pretreatment level or was >20 ng/mL. BMD for hip and spine was the primary endpoint; assessed at baseline; completion of initial treatment period; and at 1 and 2 years after initial treatment (POST period). Osteoporosis increased from 7% at baseline to 10% at 3 years. The BMD declined after 9 months treatment, at -1.9% and -3.3% at hip and spine, respectively (P < 0.001). Subsequent BMD decline in the POST period was attenuated; at 1 years and 2 years later, hip -0.6% (not significant), and -0.8% (P < 0.014), and spine +1.0% and +0.2% (not significant). The BMD change in those remaining 'off' therapy for 2 years (n = 20) was strongly associated with the level of testosterone recovery; a peak testosterone level of <5 nmol/L associated with a greater then normal physiological loss. Testosterone recovery was less likely in older men. The attenuation of spine and hip BMD decline after 3-year IAST compared with those reported for continuous AST appears to be due to testosterone driven BMD recovery in the POST period. Failure of testosterone recovery was associated with worse final BMD. By reducing the potential risk for adverse bone complications, intermittent therapy may become an important consideration when the therapeutic ratio is narrow.

(PDF emailed within 0-6 h: $19.90)

Accession: 054163921

Download citation: RISBibTeXText

PMID: 19281463

DOI: 10.1111/j.1464-410X.2009.08458.x


Related references

Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. Bju International 96(4): 514-520, 2005

Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. Journal of Clinical Oncology 30(15): 1864-1870, 2012

The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression. Journal of Urology 187(6): 2162-2166, 2013

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64(6): 1182-1186, 2004

A double-blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. Bone (New York) 20(4 SUPPL ): 100S, 1997

The effects of increased dietary calcium intake on bone mineral density in long-term lactating women, and recovery of bone loss caused by long-term lactation with low calcium diet. Japanese Journal of Public Health 51(12): 1008-1017, 2005

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 53(5): 351-356, 1998

Effect of long-term oral anticoagulant therapy on bone mineral density and bone turnover markers: a prospective 12 month study. Bratislavske Lekarske Listy 112(2): 71-76, 2011

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15(2): 96-102, 2012

Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporosis International 15(3): 180-189, 2004

A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. Bmj Open 5(6): E006957, 2016

Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: an observational, preliminary study. European Journal of Contraception and Reproductive Health Care 18(5): 388-393, 2014

Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer. Bju International 95(6): 776-779, 2005

Month 3 and month 6 measurements of bone mineral density predict the annual outcome in postmenopausal women with osteoporosis in whom alendronate was added to long-term HRT. Maturitas 44(4): 287-292, April 25, 2003